Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.
The host cell protein cyclophilin A (CypA) binds to CA of human immunodeficiency virus type 1 (HIV-1) and promotes HIV-1 infection of target cells. Disruption of the CypA-CA interaction, either by mutation of the CA residue at G89 or P90 or with the immunosuppressive drug cyclosporine (CsA), reduces HIV-1 infection. Two CA mutants, A92E and G94D, previously were identified by selection for growth of wild-type HIV-1 in cultures of CD4(+) HeLa cell cultures containing CsA. Interestingly, infection of some cell lines by these mutants is enhanced in the presence of CsA, while in other cell lines these mutants are minimally affected by the drug. Little is known about this cell-dependent phenotype of the A92E and G94D mutants, except that it is not dependent on expression of the host factor TRIM5alpha. Here, we show that infection by the A92E and G94D mutants is restricted at an early post-entry stage of the HIV-1 life cycle. Analysis of heterokaryons between CsA-dependent HeLa-P4 cells and CsA-independent 293T cells indicated that the CsA-dependent infection by A92E and G94D mutants is due to a dominant cellular restriction. We also show that addition of CsA to target cells inhibits infection by wild-type HIV-1 prior to reverse transcription. Collectively, these results support the existence of a cell-specific human cellular factor capable of restricting HIV-1 at an early post-entry step by a CypA-dependent mechanism.
Song
Chisu
C
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, A-5301 Medical Center North, Nashville, TN 37232-2363, USA.
Aiken
Christopher
C
D019380:Anti-HIV Agents / Q000494:pharmacology; D002467:Cell Nucleus / Q000378:metabolism / Q000821:virology; D016572:Cyclosporine / Q000494:pharmacology*; D003593:Cytoplasm / Q000821:virology; D004351:Drug Resistance; D005434:Flow Cytometry; D005799:Genes, Dominant; D015497:HIV-1 / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D009154:Mutation; D010957:Plasmids / Q000378:metabolism; D014771:Virion / Q000378:metabolism; D014779:Virus Replication
D019380:Anti-HIV Agents; D016572:Cyclosporine
J Virol. 2006 May;80(10):4683-90
16641261
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5381-5
7777516
J Virol. 1998 May;72(5):3845-50
9557668
J Virol. 2003 Jul;77(14):7779-85
12829817
J Virol. 1994 Feb;68(2):1179-85
8289347
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11920-5
12154231
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13843-8
12368468
Nature. 2004 Feb 26;427(6977):848-53
14985764
J Med Virol. 1995 Oct;47(2):172-8
8830122
J Virol. 2002 May;76(9):4671-7
11932436
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1298-303
12547912
Virology. 1998 Nov 10;251(1):1-15
9813197
J Virol. 2005 Sep;79(18):11569-79
16140734
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13324-8
15326303
Virology. 2000 Mar 15;268(2):294-307
10704338
Structure. 1997 Jan 15;5(1):139-46
9016720
Nat Struct Biol. 2003 Jun;10(6):475-81
12730686
EMBO J. 1999 Dec 1;18(23):6771-85
10581250
Science. 1984 Nov 2;226(4674):544-7
6238408
Nat Med. 2001 May;7(5):631-4
11329067
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14849-53
16203999
Blood. 1988 Dec;72(6):1904-10
2904290
J Virol. 2006 Apr;80(8):3712-20
16571788
J Virol. 1998 Jan;72(1):303-8
9420228
Retrovirology. 2004;1:9
15169567
Nature. 1994 Nov 24;372(6504):359-62
7969494
EMBO J. 2003 Feb 3;22(3):385-94
12554640
J Virol. 2002 Jun;76(11):5667-77
11991995
J Immunol. 2006 Jul 1;177(1):443-9
16785541
J Virol. 2002 Nov;76(22):11440-6
12388705
J Virol. 2005 Jan;79(1):176-83
15596813
J Virol. 2004 Apr;78(7):3429-35
15016865
J Virol. 1996 Jun;70(6):3551-60
8648689
Nat Med. 2003 Sep;9(9):1138-43
12897779
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11827-32
15280539
Nature. 1997 Feb 13;385(6617):645-9
9024664
J Virol. 1997 Sep;71(9):7110-3
9261445
Methods. 1997 Aug;12(4):288-93
9245608
EMBO J. 2001 Mar 15;20(6):1300-9
11250896
Curr Opin HIV AIDS. 2006 May;1(3):194-9
19372808
J Virol. 1996 Jun;70(6):3536-44
8648687
Virology. 1996 Aug 1;222(1):279-82
8806510
J Virol. 2007 Apr;81(8):3749-56
17267487
J Virol. 1995 Apr;69(4):2451-61
7884893
Nature. 1989 Feb 2;337(6206):473-5
2644542
Methods Cell Biol. 1994;43 Pt A:99-112
7823872
Protein Sci. 1997 Nov;6(11):2297-307
9385632
Nature. 1994 Nov 24;372(6504):363-5
7969495
J Virol. 2007 Feb;81(3):1534-6
17108041
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11914-9
12154227
Nat Biotechnol. 2002 Nov;20(11):1151-4
12355096
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15154-9
14657387
Antimicrob Agents Chemother. 1994 Aug;38(8):1763-72
7527198
Nucleic Acids Res. 2002 Jan 15;30(2):E9
11788735
Virology. 2006 Mar 15;346(2):460-8
16375941
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10780-5
15249687
J Virol. 1998 Aug;72(8):6430-6
9658084
J Virol. 1996 Aug;70(8):5170-6
8764025
Cell. 1993 Jun 18;73(6):1067-78
8513493
Cell. 1996 Dec 27;87(7):1285-94
8980234
J Virol. 2004 Nov;78(21):11739-50
15479815
J Virol. 2004 Nov;78(21):12066-70
15479848
Nature. 1989 Feb 2;337(6206):476-8
2492638
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10786-91
15249690
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10774-9
15249685
J Virol. 2004 Dec;78(23):12800-8
15542632
Curr Top Microbiol Immunol. 1996;214:95-131
8791726
Nat Med. 1998 Dec;4(12):1397-400
9846577
J Mol Biol. 1997 Jun 27;269(5):780-95
9223641
J Virol. 1998 Apr;72(4):2846-54
9525604
Nature. 2004 Jul 29;430(6999):569-73
15243629